Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.

摘要: In recent years, we have made huge strides in our understanding of the molecular complexity diffuse large B-cell lymphoma (DLBCL). New technologies, such as gene expression profiling, RNA interference screening, and DNA sequencing, identified several new signaling pathways therapeutic targets for drug development. While once considered DLBCL to be a single disease entity, insights helped identify existence at least three distinct diseases: germinal center B-cell-like subtype, an activated primary mediastinal subtype. All subtypes originate from different stages differentiation are characterized by mechanisms oncogenic activation. This classification has laid foundation development agents novel strategies that target individual subtypes.